RBCC: Analyst Rates n3D a Leading Stakeholder in Explosive Bioprinting Industry

A new research publication lists Rainbow Coral Corp. (OTCBB: RBCC) Nano3D Biosciences (n3D) as a leading stakeholder in an industry forecast to be worth $10 billion by 2030.

3D Bioprinting Market, 2014-2030 by Roots Analysis details the widespread optimism that bioprinting technology will rise dramatically in prominence in the coming years, impacting the daily lives of millions of people. With techniques and technology advancing rapidly, RBCC has positioned itself on the front lines of 3D bioprinting research through its joint venture with Nano3D Biosciences (n3D). The companies have teamed up to market and develop the 3D BiO Assay, the first commercially available 3D bioprinting system designed specifically for rapid, high-volume drug screening.

The publication provides deep insights into leading stakeholders in the nascent industry, including n3D. As a company producing commercially available bioprinters, n3D is examined as one of seven that currently own the majority hold in the marketplace. The major customers for these bioprinters are universities and research institutes, where they are being used for breakthrough research and production.

“There is a growing need for more bioprinters in the market that can utilize different technologies to suit the need of pharmaceutical companies,” said RBCC CEO Kimberly Palmer. “Our development partnership with n3D puts us at the forefront of the movement to supply their labs with game-changing innovations.”

RBCC formed a biotech subsidiary, Rainbow Biosciences, to market and develop new medical and research technology innovations to compete alongside companies such as Biogen Idec Inc. (NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen Inc. (NASDAQ: AMGN). In 2012, Rainbow Biosciences acquired an equity interest in n3D.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.